When to Move Up on Mounjaro: A Step-by-Step Guide to Dose Escalation

Step 1: Why 2.5 mg is the starting point, and what happens at week four

Tirzepatide's licensed schedule begins at 2.5 mg for one reason above all others: tolerability. The gut-hormone pathways this medicine activates can cause nausea, stomach discomfort and altered bowel habits, especially in the first days after a new dose. Starting low gives your system time to settle before the dose that does the therapeutic work kicks in.

Four weeks in, the question your prescriber is really asking is not "has enough time passed?" but "is your body ready to handle more?" If side effects from 2.5 mg are still significant (persistent nausea, vomiting that is not settling, inability to eat normally) rushing upward rarely helps. Staying at the current dose for another four weeks while symptoms ease is a legitimate, sensible clinical choice.

If, on the other hand, you've tolerated 2.5 mg well and want to understand the full picture of how each dose typically behaves, our Mounjaro overview covers what the clinical programme showed at different dose levels. The practical detail of what to actually do week to week on treatment, including when to take Mounjaro and how to time your injections, is covered in our guide to life on Mounjaro.

Step 2: The four-week minimum, and when it's right to hold

Every dose increase requires a minimum of four weeks at the current level. That is the licensed schedule, full stop. What varies is whether four weeks is also the right time to move, or whether holding steady for longer makes better clinical sense.

Reasons to hold rather than increase include: GI side effects that are still disruptive; a period of illness or stress that made it hard to assess your normal response; a planned trip or change in routine that makes starting a higher dose inconvenient, a question our prescribers hear fairly often is whether to time a dose increase around a holiday or a busy stretch at work, and the honest answer is that a short planned hold at a stable dose is usually far safer than escalating into an unpredictable few weeks.

Evidence of inadequate weight response alone is not always a reason to escalate immediately either. The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing should be reviewed, not that every earlier dose should be rushed through. The therapeutic dose is the one that works for you, at a pace your body accepts.

Step 3: Signs that a dose increase is probably appropriate

Your prescriber is looking for a cluster of signals, not a single threshold. Good candidates for moving up typically show: stable tolerability at the current dose for several weeks; side effects that have settled rather than persisted; a plateau or slowing in weight response after initial progress; and no current contraindication to a higher dose (recent significant illness, surgery, or a new medication that interacts).

Weight loss trajectory matters here. Some people lose steadily at 5 mg and stay there for months; others plateau early and benefit from escalating toward 10 mg or 12.5 mg. The SURMOUNT-1 trial, involving over 2,500 adults with obesity, showed the largest average reductions at the higher doses, which is why the escalation protocol exists. But those results came from a clinical trial with structured oversight, not self-directed dose increases.

If you're weighing up whether your current dose is still doing its job, our page on whether to move up on Mounjaro goes into that specific decision in more detail. For anyone thinking about the opposite question, the considerations around when to stop Mounjaro are equally worth understanding before any clinical conversation.

Step 4: The prescriber review, what happens at nume before every repeat

At nume, you do not simply reorder and receive the next pen up. A GPhC-registered Independent Prescriber reads your repeat questionnaire, checks your reported weight, reviews any side effects you've flagged, and makes a clinical decision. A real clinician reviews each case the same day; your answers go to a prescriber's desk, not into an automated queue.

This matters most at dose-increase points. Evidence of your current weight and any relevant health changes is assessed before escalation is approved. If something in your response gives pause (new symptoms, a missed-dose pattern, signs that the current dose is not well tolerated) your prescriber may ask for more information or suggest staying at the current level. That is not a barrier; it is the process working as it should.

The cost of Mounjaro at different doses is a practical consideration too (higher doses carry higher list prices since Eli Lilly's 2025 pricing changes) and it's worth understanding the full picture before escalating. If you'd like to explore your options with our clinical team, start a free consultation and a prescriber will assess which step is right for you.